Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 10

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 10
---
that such legal proceedings may result in significant costs of defense, indemnification and liability; the failure (or delay) to receive
the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; disruption from the
proposed transactions, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers;
the risk that Parent will not be able to retain the employees of Target following the closing of the transaction given the at-will nature
of their employment; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that
such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not
occur; risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing
of clinical trials and reporting data; risks related to future opportunities and plans for Target and its product candidates, including
uncertainty of the expected financial performance of Target and its product candidates and the possibility that the Milestone Payments
related to the CVRs will never be achieved and that no Milestone Payment may be made; the possibility that if Target does not achieve
the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market
price of Parent’s shares could decline; as well as other risks related to Parent’s and Target’s businesses detailed from time-to-time under the
caption “Risk Factors” and elsewhere in Parent’s and Target’s respective SEC filings and reports, including their
respective Annual Reports on Form 10-K for the year ended December 31, 2024 and subsequent quarterly and current
reports filed with the SEC. Parent undertakes no duty or obligation to update any forward-looking statements contained in this report
as a result of new information, future events or changes in their expectations, except as required by law.

Additional Information and Where to Find It

The Offer has not yet commenced, and this
report is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any Target Shares or any other securities.
On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal
and related documents, will be filed with the SEC by Parent and Merger Sub, and a Solicitation/Recommendation Statement on Schedule 14D-9 will be
filed with the SEC by the Target. The offer to purchase Target